Gene Therapy (Zynteglo for Beta-Thalassemia)

Type: gene_therapy

Status: EMA Approved (withdrawn from EU market due to commercial reasons), FDA Approved

Developer: bluebird bio

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026